New sophisticated chip was found to mimic the effects of osteoarthritis (OA) to develop effective drugs. The chip is in the size of a coin in which cartilage can be cultivated and which can later be subjected to mechanical stress. This is the extraordinary result achieved at the Politecnico di Milano Laboratory MiMic (Microfluidic and Biomimetic Microsystems) by Marco Rasponi from the Milan-based campus, the study's coordinator alongside Andrea Barbero from the University Hospital of Basel.
The study was published in Nature Biomedical Engineering.
Hip replacement
Are you experiencing pain due to damaged hips? Travel abroad to get replacement surgery at affordable prices.
Advertisement
‘Over the age of sixty, 10% of men and 20% of women will suffer from its effects, numbers which unfortunately are set to increase due to the current rate of population ageing. ’
Tweet it Now
Not only did it produce the revolutionary chip but, while the tiny device was undergoing experimentation, the study also demonstrated that the mechanical hyperstimulation of cartilage seems to be enough to induce Osteoarthrosis-related pathology, without having to turn to administering inflammatory molecules as was common practice up until now.
Indeed, appropriate compression of the cartilaginous tissue can induce typical symptoms of OA: inflammation, hypertrophy and an acceleration of degenerative processes. Therefore, in the cartilage "on a chip" an ideal environment is created in which to test the effectiveness and mechanisms of pharmacological treatments, shortening the timeframes and costs of experimentation while also reducing the need for animal testing.
![Osteoarthritis]( "Osteoarthritis")
Osteoarthritis is one of the commonest joint disorder and occurs as we age due to wear and tear of a joint. Osteoarthritis can affect any joint of the body.
Osteoarthrosis is the most common among musculoskeletal pathologies. However, despite this trend, patients find themselves facing a complete lack of pharmacological therapy, known as DMOADs (Disease modifying Osteoarthritis Drugs): pharmaceuticals, that is, which are capable of not only alleviating the symptoms but also halting or reversing the degenerative processes. In fact, currently the only valid options are palliative treatment or surgery.
The development of effective drugs was hindered by an absence of experimental models that could adequately replicate the pathology.
Up until now the most common approach to reproduce OA in vitro has been based on administering high doses of molecules into cartilage explants, capable of inducing an inflammatory response and some form of catabolism. Yet the OA obtained in this manner can only partially represent the final symptoms, instead of demonstrating the pathological process in real time. The new chip, on the other hand, uses mechanical stress, representing one of the factors that are most closely connected to the development of OA, and is thus more realistic and more effective in its development and pharmacological screening procedures.
The research will continue towards modelling an entire joint on a chip, thanks to a project initiated by the Cariplo Foundation, having been granted funding following the call for "Biomedical research on age-related diseases 2018". The project is named "uKNEEque: a 3D microfluidic osteochondral model to investigate mechanisms triggering age-related joint pathologies and therapeutic effects of bioactive factors produced by nasal chondrocytes". The Politecnico di Milano is coordinating the research with the University Hospital of Basel as a Partner.
Source: Eurekalert
Osteoarthritis
Osteoarthritis is one of the commonest joint disorder and occurs as we age due to wear and tear of a joint. Osteoarthritis can affect any joint of the body.
Advertisement
Osteoarthrosis is the most common among musculoskeletal pathologies. However, despite this trend, patients find themselves facing a complete lack of pharmacological therapy, known as DMOADs (Disease modifying Osteoarthritis Drugs): pharmaceuticals, that is, which are capable of not only alleviating the symptoms but also halting or reversing the degenerative processes. In fact, currently the only valid options are palliative treatment or surgery.
The development of effective drugs was hindered by an absence of experimental models that could adequately replicate the pathology.
Up until now the most common approach to reproduce OA in vitro has been based on administering high doses of molecules into cartilage explants, capable of inducing an inflammatory response and some form of catabolism. Yet the OA obtained in this manner can only partially represent the final symptoms, instead of demonstrating the pathological process in real time. The new chip, on the other hand, uses mechanical stress, representing one of the factors that are most closely connected to the development of OA, and is thus more realistic and more effective in its development and pharmacological screening procedures.
The research will continue towards modelling an entire joint on a chip, thanks to a project initiated by the Cariplo Foundation, having been granted funding following the call for "Biomedical research on age-related diseases 2018". The project is named "uKNEEque: a 3D microfluidic osteochondral model to investigate mechanisms triggering age-related joint pathologies and therapeutic effects of bioactive factors produced by nasal chondrocytes". The Politecnico di Milano is coordinating the research with the University Hospital of Basel as a Partner.
Source: Eurekalert
Painkillers Increase Cardiovascular Risk in Osteoarthritis Patients
Nonsteroidal anti-inflammatory drugs (NSAIDs) which are prescribed to control the pain and inflammation in individuals with osteoarthritis (OA) can increase the risk of cardiovascular diseases.
Advertisement
Osteoarthritis Tied to a Higher Risk of Dying from Heart DiseaseRisk of dying from heart disease is higher in people with osteoarthritis, finds a new study | Advertisement
|
Advertisement
Recommended Readings
Latest Research News
South Korea's total fertility rate, averaging the number of children a woman aged 15-49 has in her lifetime, dropped to 0.81.
Scientists identified mechanisms governing immune cells, selectively removing troublemakers to reshape skin immunity. Benefits those with psoriasis, vitiligo.
By 2050, an anticipated increase from 494 million cases in 2020 to 1.06 billion people with musculoskeletal disabilities is expected.
Experts consulted by GlobalData anticipate a significant overhaul in the Gaucher disease scenario because of forthcoming gene therapies in development.
Within the seven major markets, 12% to 20% of diagnosed prevalent NASH cases present severe liver damage (stage 4 liver fibrosis), denoting cirrhosis.